(Reuters) – Aerovate Therapeutics said on Monday it is shutting down the late-stage portion of a study testing its experimental hypertension drug after failing to meet the main goal in a mid-stage trial.
(Reporting by Pratik Jain in Bengaluru; Editing by Krishna Chandra Eluri)
Comments